PF-04191834 Single Dose Bronchodilatory Study In Asthma.

A Phase 2a, Randomised, Double-Blind (3rd Party Open), Double-Dummy, Placebo And Active Controlled 5-Way Crossover Study To Assess The Bronchodilatory Action, Safety, Toleration And Pharmacokinetics Of Single Oral Doses Of PF-04191834 In Asthmatic Patients.

Study to determine the bronchodilatory effects of PF-04191834 compared with zileuton in patients with asthma

Inclusion Criteria:

• Persistent mild/moderate asthma for at least 6 months.
• Reduced lung function
• Reversible airway obstruction

Exclusion Criteria:

• Pregnant/nursing females.
• Liver function tests greater than upper limit of normal (ULN)